Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine (CC-486) Alone or with Durvalumab in MDS
NCT02281084Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2015
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of CC-486 in myelodysplastic syndrome (MDS) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Overall Response Rate up to 91 months. Started Jul 2015; status: completed.
02
Drugs
CC-486
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02281084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281084.